Commerce Secretary Howard Lutnick announced that AstraZeneca plans to build a $50 billion manufacturing facility in the United States. This investment aims to create many high-paying jobs in Virginia, Indiana, Texas, and across the country. The facility will help strengthen supply chains and support the broader goal of bringing pharmaceutical production back to the U.S. This aligns with one of the key goals of the current administration. We think Mr. Lutnick’s plan is a strong positive sign for AstraZeneca in the near future. Traders might consider buying call options that expire in the next 30 to 60 days to speculate on possible price increases due to this huge investment. The size of the investment is likely to boost investor confidence beyond what is already seen in the stock price. This announcement comes as AstraZeneca’s stock is already performing well, rising over 15% this year and nearing all-time highs, mostly due to strong sales in oncology. The news about a new U.S. facility could push the stock even higher. Therefore, strategies like selling out-of-the-money put options might be attractive to earn premiums while staying optimistic. This positive sentiment is also visible in the broader sector, with the iShares U.S. Pharmaceutical ETF (IHE) showing steady gains. We expect that implied volatility for AstraZeneca will increase in the next few days, as the market considers both the opportunities and risks involved. This could be a chance to sell volatility through strategies like short straddles, especially if a trader thinks the initial price rise will be followed by a period of calm. Historically, after major factory announcements, stocks often see an initial jump followed by more scrutiny of project timelines and costs. The focus on strengthening supply chains highlights a broader trend beyond just AstraZeneca. We are also looking at call options for U.S.-based contract development and manufacturing organizations (CDMOs) and industrial real estate investment trusts (REITs) in the relevant states. This reshoring initiative is similar to the government’s CHIPS Act, which supported the domestic semiconductor industry. In the coming weeks, we’ll monitor options volume and open interest for signs of significant institutional buying. A noticeable increase in call volume compared to put volume would confirm our optimistic outlook. Our main focus should be on short-term contracts to take advantage of the immediate positive response to this news.

here to set up a live account on VT Markets now